Wu Guangjun Won the First "Eight Wu Craftsman" Title of Jinhua
Release time:
2020-08-14
Wu Guangjun Won the Title of Jinhua's First "Ba Wu Craftsman"
News At the Jinhua City Celebration of "May 1" International Labor Day and the City's First Ba Wu Craftsman Naming Conference held on 4# August 27 , Wu Guangjun, Electrical Director of Jinxi Pharmaceutical Factory of Pharmaceutical Company, Won the Title of "Ba Wu Craftsman.
The first "Badu Craftsman" selection requires candidates to have been engaged in professional skills in Jinhua City for no less than 10 years, and are still engaged in production, technology, research and development, artwork Creation and other jobs, professional skills are at the highest level in the city, and there are major inventions or major technological innovations in technology, outstanding contributions have been made in the technological transformation of enterprises, the introduction and absorption of high and new technologies, the solution of key technical problems, and the elimination of major security risks; candidates must study hard in the fields of Jinhua characteristics, traditional classic industries, traditional handicrafts (such as arts and crafts), etc., products (works) pursue excellence, and have considerable influence in this industry and field. At the end of
2016 , Jinhua Federation of Trade Unions launched the first "Eight Wu Craftsmen" recommendation and selection work in the city. After layers of recommendation, and by the county (city, district) labor competition committee and the municipal system work committee, industrial trade union through screening, review, network selection, expert committee review, leading group review and other links strictly selected, the selection work was recently completed.
Comrade Wu Guangjun has been working for 29 and has been sticking to the front line of hard work and selfless dedication. Although his education level is not high, he has continuously enriched his professional theoretical knowledge through hard work to reach the junior college level. 29 years such as a day of meticulous work accumulation, his practical ability, technical level by leaps and bounds to improve, grow into a senior technician and enterprise indispensable electrical supervisor. Over the years, he has completed more than 27 120 28 items of technological transformation and innovation alone or with his team, including more than 29 20 30 items of major technological transformation, and has won honors such as gold medal employee and outstanding party member of the group company. (Pharmaceutical Company)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31